

# China policies to promote local production of pharmaceutical products and protect public health



IP  
Intellectual  
Property and Trade

R&D  
Innovation

TT  
Technology  
Transfer

IA  
Improving Access

FI  
Financing

MR  
Monitoring and  
Reporting



European  
Commission



World Health  
Organization



# China policies to promote local production of pharmaceutical products and protect public health



European  
Commission |



World Health  
Organization

China policies to promote local production of pharmaceutical products and protect public health

ISBN 978-92-4-151217-6

© **World Health Organization 2017**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** China policies to promote local production of pharmaceutical products and protect public health. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Editing and design by Inís Communication – [www.iniscommunication.com](http://www.iniscommunication.com)

# Contents

<b>Abbreviations and Acronyms</b> . . . . .	<b>iv</b>
<b>Acknowledgements</b> . . . . .	<b>vi</b>
<b>Executive summary</b> . . . . .	<b>1</b>
<b>I. Overview</b> . . . . .	<b>4</b>
<b>II. Regulatory reform</b> . . . . .	<b>8</b>
<b>III. China's Pharmaceutical Sector</b> . . . . .	<b>16</b>
<b>IV. Distribution</b> . . . . .	<b>27</b>
<b>V. Innovation and technology transfer</b> . . . . .	<b>29</b>
<b>VI. The Role of Intellectual Property</b> . . . . .	<b>32</b>
<b>VII. Competition Law</b> . . . . .	<b>34</b>
<b>VIII. Modelling for local production and transfer of technology</b> . . . . .	<b>35</b>
<b>Appendix 1: Questions for interviewees in China regarding country models for the promotion of the pharmaceutical production sector</b> . . . . .	<b>40</b>
<b>Appendix 2: List of interviewee organizations</b> . . . . .	<b>45</b>
<b>Appendix 3: Project Concept Note</b> . . . . .	<b>46</b>
<b>Annex 1 – List of Government Departments/Agencies of Interest</b> . . . . .	<b>49</b>

## Abbreviations and Acronyms

<b>ANDA</b>	abbreviated new drug application
<b>API</b>	active pharmaceutical ingredient
<b>BMI</b>	basic medical insurance
<b>CDE</b>	Center for Drug Evaluation
<b>CDFA</b>	China Food and Drug Administration
<b>ChP</b>	Chinese Pharmacopeia
<b>CPC</b>	Chinese Pharmacopeia Commission
<b>CRO</b>	contract research organization
<b>EML</b>	essential medicines list
<b>EMA</b>	European Medicines Agency
<b>FDI</b>	foreign direct investment
<b>FPP</b>	finished pharmaceutical product
<b>GMP</b>	good manufacturing practice
<b>GSPA</b>	Global Strategy and Plan of Action
<b>HIC</b>	high-income country
<b>IP</b>	intellectual property
<b>MAH</b>	marketing authorization holder
<b>MNC</b>	multinational corporation
<b>MOFCOM</b>	Ministry of Commerce of the People's Republic of China
<b>NDA</b>	new drug application
<b>NDRC</b>	National Development and Reform Commission
<b>MPP</b>	Medicines Patent Pool
<b>MOH</b>	Ministry of Health
<b>NHFPC</b>	National Health and Family Planning Commission
<b>OTC</b>	over-the-counter
<b>PHI</b>	Public Health, Innovation and Intellectual Property
<b>PRC</b>	People's Republic of China
<b>R&amp;D</b>	research and development
<b>SAIC</b>	State Administration for Industry and Commerce
<b>SIPO</b>	State Intellectual Property Office
<b>SOE</b>	state-owned enterprise
<b>SEZ</b>	special economic zone

<b>TCM</b>	traditional Chinese medicine
<b>UHC</b>	universal health care
<b>US FDA</b>	United States Food and Drug Administration
<b>US PTO</b>	United States Patent and Trademark Office
<b>USP</b>	United States Pharmacopeia Convention
<b>VAT</b>	value-added tax
<b>WHO</b>	World Health Organization
<b>WTO</b>	World Trade Organization

# CHINA REPORT

## Acknowledgements

This study and report were made possible by the generous support of the European Commission, through the World Health Organization (WHO) local production project *Improving access to medical products in developing countries through capacity building for local production and related technology transfer*. This report was prepared by Professor Frederick Abbott, WHO consultant.

This report benefits from information gathered in connection with a visit to China in June 2016 by Professor Abbott and Dr Jicui Dong, Programme Manager for Local Production, WHO Department of Essential Medicines and Health Products (EMP). We thank our hosts at the China Food and Drug Administration (CFDA), China's National Health and Family Planning Commission (NHFPC), the State Administration of Traditional Chinese Medicine (SATCM), the China Chamber of Commerce for Import & Export of Medicines and Health Products (CCCMHPIE), the Xiyuan Hospital of the China Academy of Chinese Medical Sciences and the Gates Foundation China Office. Particular thanks are owed to Dr Xu Ming, Vice President of CCCMHPIE for providing an overview of the Chinese pharmaceutical sector and organizing discussions with representatives of the Chinese pharmaceutical industry; Dr Sun Yang, Deputy Director-General of the Department of Drug Policy and Essential Medicines at NHFPC for providing a detailed overview of China's national health care structure; Dr Zhu Haidong, Deputy Director-General of the International Cooperation Department at SATCM for furnishing information on traditional Chinese medicine, and; Mr Wang Xiangyu, Director of the Division of International Organizations at CFDA for providing information relating to regulatory matters. Additional thanks are owed to Dr LIU Yue, Director of the Department of International Cooperation at NHFPC, Ms Chen Yuan, Program Officer at the Bill & Melinda Gates Foundation China Office, as well other Chinese colleagues and representatives from the Chinese pharmaceutical industry who took part in interviews and discussions.

Special thanks to the China Office of WHO for organizing and coordinating local arrangements for the discussions in China, with particular thanks to Ms Noura Maalaoui, Technical Officer, Mr Fabio Scani, Coordinator and Dr Bernhard Schwartlander, WHO Representative at the China Office.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26426](https://www.yunbaogao.cn/report/index/report?reportId=5_26426)

